# A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer

> **NCT06516510** · EARLY_PHASE1 · TERMINATED · sponsor: **Blue Earth Therapeutics Ltd** · enrollment: 17 (actual)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **DRUG:** lutetium (177Lu) rhPSMA 10.1 and Pluvicto®

## Key facts

- **NCT ID:** NCT06516510
- **Lead sponsor:** Blue Earth Therapeutics Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-10-31
- **Primary completion:** 2025-08-15
- **Final completion:** 2025-08-15
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Based on data from the Interim Analysis, the study will not adequately inform the clinical development programme for Lutetium (177Lu) rhPSMA-10.1 injection in the way that the study was intended. There are no concerns regarding participant safety.
- **Last updated:** 2025-09-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06516510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06516510, "A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06516510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*